title: 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
abstract: OBJECTIVE
  To evaluate response and survival according to (18)F-fluoro-2-deoxy-glucose uptake at presentation in patients with gefitinib-treated non-small cell lung cancer.
  
  
  METHODS
  We retrospectively analyzed 84 positron emission tomography/computed tomography findings. Patient characteristics, response rates, and survivals were evaluated according to the maximum standardized uptake value (SUV) of primary tumor. The cutoff value of SUVs was obtained from receiver operating characteristic analysis.
  
  
  RESULTS
  The response rate (RR) was higher for never-smokers (41%) than ever-smokers (9%; P=0.001). Patients with adenocarcinoma showed higher RR than those with other tumor histopathology (35% versus 9%; P=0.009). The SUV was significantly lower in patients who were never-smokers (P=0.005), patients with adenocarcinoma (P<0.001), and female patients (P=0.017). Patients with a low SUV showed higher RR compared with those with a high SUV (53% versus 18%; P=0.003). Prolonged progression-free survival was observed in patients with low SUVs compared with those with high SUVs (median, 33.1 weeks versus 8.6 weeks; P=0.003). While controlling for performance status, smoking history, and pathology, the high SUV conferred unfavorable outcome (hazard ratio, 2.3; P=0.012). In terms of overall survival, a low SUV was associated with favorable outcome in univariate analysis (P=0.011). Patients with a low SUV showed prolonged survival in multivariate analysis (P=0.043).
  
  
  CONCLUSIONS
  These results suggest that low SUVs at presentation can predict favorable response and survival in gefitinib-treated non-small cell lung cancer patients.
authors.affiliation: Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon-gu, Seoul, Korea. hmonaimil@yahoo.com
authors.forename: Im Il
authors.initials: II
authors.lastname: Na
authors.forename: Byung Hyun
authors.initials: BH
authors.lastname: Byun
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kang
authors.forename: Gi Jeong
authors.initials: GJ
authors.lastname: Cheon
authors.forename: Jae Soo
authors.initials: JS
authors.lastname: Koh
authors.forename: Cheol Hyeon
authors.initials: CH
authors.lastname: Kim
authors.forename: Du Hwan
authors.initials: DH
authors.lastname: Choe
authors.forename: Baek-Yeol
authors.initials: BY
authors.lastname: Ryoo
authors.forename: Jae Cheol
authors.initials: JC
authors.lastname: Lee
authors.forename: Sang Moo
authors.initials: SM
authors.lastname: Lim
authors.forename: Sung Hyun
authors.initials: SH
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011799:Quinazolines / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000378:metabolism; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000077156:Gefitinib